

(12) UK Patent Application (19) GB (11) 2 294 879 (13) A

(43) Date of A Publication 15.05.1996

(21) Application No 9520615.7

(22) Date of Filing 09.10.1995

(30) Priority Data

(31) 325759

(32) 19.10.1994

(33) US

(71) Applicant(s)

Merck & Co Inc

(Incorporated in USA - New Jersey)

P O Box 2000, 126 East Lincoln Avenue, Rahway,
New Jersey 07065-0900, United States of America

(72) Inventor(s)

Edward M Scolnick

(74) Agent and/or Address for Service

W G Cole

Merck & Co Inc, European Patent Department,
Terlings Park, Eastwick Road, HARLOW, Essex,
CM20 2QR, United Kingdom

(51) INT CL⁶

A61K 31/34

(52) UK CL (Edition O)

A5B BHA B180 B33Y B33Z B42Y B420 B48Y B480 B482

B484 B485 B50Y B503 B54Y B540 B55Y B551 B56Y

B565 B57Y B576 B58Y B586 B60Y B606 B61Y B616

B65Y B650

U1S S2416

(56) Documents Cited

GB 2283745 A WO 95/21817 A1 WO 94/26731 A1

WO 94/15932 A1 WO 94/13835 A1

European J. Clin. Pharmacol. Vol. 47 (1) 1994. Suppl.
A52

(58) Field of Search


UK CL (Edition O) A5B BHA BJA BJB

INT CL⁶ A61K

ONLINE: CAS ONLINE, DIALOG/MEDICINE, WPI

(54) Cyclooxygenase-2 Inhibitors

(57) There are described cyclooxygenase-2 inhibitors for medical use, preferably for the treatment of bone disorders, particularly bone resorption. Preferably the inhibitors have the formula:



wherein R¹ is selected from the group consisting of

(a) S(O)₂CH₃,

(b) S(O)₂NH₂,

(c) S(O)₂NHC(O)CF₃,

(d) S(O)NHCH₃,

(e) S(O)NHNH₂,

(f) S(O)NHNHC(O)CF₃,

and R² is selected from the group consisting of

(a) C 1 - 6 alkyl,

(b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,

(c) mono-, di or tri-substituted phenyl or naphthyl groups

or repr sent pharmaceutically acceptable salts thereof.

GB 2 294 879 A

TITLE OF THE INVENTION
METHOD OF PREVENTING BONE LOSS

BACKGROUND OF THE INVENTION

5 The invention relates to a method of inhibiting bone resorption, halting or retarding loss of bone mass, reducing fractures, improving bone repair and preventing or treating osteoporosis, particularly in post-menopausal women. Treatment of additional diseases/disorders is also disclosed.

10 The current major bone diseases of public concern include osteoporosis (post-menopausal, idiopathic and secondary to immobilization or drugs such as glucocorticoids), bone lesions due to metastases, hypercalcemia of malignancy, oral bone loss due to periodontal disease, hyperparathyroidism, periarticular erosions in
15 rheumatoid arthritis and Paget's disease.

 All these conditions are characterized by bone loss, resulting from an imbalance between bone resorption (breakdown) and bone formation. This process of bone remodeling or bone turnover continues throughout life and replaces about 14% of the skeletal mass
20 per year on the average. However, the rate of bone turnover differs from site to site, for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones. The potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately
25 following menopause, a condition which leads to increased fracture risk.

 There are currently 20 million people with detectable fractures of the vertebrae due to osteoporosis in the United States. In addition, there are 250,000 hip fractures per year attributed to osteoporosis. This clinical situation is associated with a 12-20%
30 mortality rate within the first two years, while over 30% of the patients require nursing home care after the fracture.

 Individuals suffering from all the conditions listed above would benefit from treatment with agents which inhibit bone resorption.

There is evidence in the literature that prostaglandins act as modulators of the bone resorption process. There is also evidence that certain non-steroidal anti-inflammatory agents (NSAID's) may (to some degree) reduce bone resorption. See, for example, the reports on the
5 use of Diclofenac sodium by post menopausal women (*Am. J. Medicine*, Vol. 96, pp. 349-353, 1994); naproxen (*J. Bone Mineral Res.*, Vol. 5, pp. 1029-1035, 1990) in laboratory animal models.

As is appreciated by those of skill in the art, the natural
10 processes of bone resorption and bone renewal are in constant dynamic equilibrium. This equilibrium, however, may differ with time (age), sex, and/or hormonal balance. Accordingly, the existence of evidence supporting the premise that the administration of an NSAID to post-menopausal women, may (to some degree) retard bone resorption, can
15 not be taken as an indicator that the administration of NSAID's will affect a sufficient shift in equilibrium to halt or retard loss of bone mass, reduce fractures, improve bone repair or provide an effective means of preventing or treating osteoporosis. See in contrast GB 2,118,042 issued January 15, 1986 (US 4,621,077) , which discloses the
20 use of bisphosphonates, including alendronate, which have been shown effective in the prevention of bone loss in post-menopausal women.


Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer
25 growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase has been characterized, this corresponding to cyclooxygenase-1 or the constitutive enzyme, as originally identified in bovine seminal vesicles. Recently the gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from
30 chicken, murine and human sources. This enzyme is distinct from the cyclooxygenase-1 which has now also been cloned, sequenced and characterized from sheep, murine and human sources. The second form of cyclooxygenase, cyclooxygenase-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones,

cytokines and growth factors. As prostaglandins have both physiological and pathological roles, evidence is mounting that the constitutive enzyme, cyclooxygenase-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, the inducible form, cyclooxygenase-2, appears to be mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines.

Surprisingly, the applicant has now found that selective cyclooxygenase-2 inhibitors, and in particular the compounds of formula I as described below are effective in inhibiting bone resorption, halting or retarding loss of bone mass, reducing fractures, improving bone repair and preventing or treating osteoporosis.

SUMMARY OF THE INVENTION

The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I.



The invention also encompasses the treatment of additional diseases and disorders as disclosed herein.

The invention also encompasses pharmaceutical compositions for the purposes described herein.


DETAILED DESCRIPTION OF THE INVENTION

5

The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to either prevent, retard, halt or reverse loss of bone mass, thereby reducing the risk of fractures, comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of Formula I

10

15



20

I

or a pharmaceutically acceptable salt thereof wherein:
X-Y-Z is selected from the group consisting of:

25

- (a) -CR⁵(R^{5'})-O-C(O)-,
- (b) -C(O)-O-CR⁵(R^{5'})-,

R¹ is selected from the group consisting of

30

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)(NH)CH₃,
- (e) S(O)(NH)NH₂,
- (f) S(O)(NH)NHC(O)CF₃,
- (g) P(O)(CH₃)OH, and
- (h) P(O)(CH₃)NH₂,

R² is selected from the group consisting of


- (a) C₁₋₆alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono-, di- or tri-substituted phenyl or naphthyl wherein
5 the substituent is selected from the group consisting of
 - (1) hydrogen,
 - (2) halo,
 - (3) C₁₋₆alkoxy,
 - (4) C₁₋₆alkylthio,
 - 10 (5) CN,
 - (6) CF₃,
 - (7) C₁₋₆alkyl,
 - (8) N₃,
 - (9) -CO₂H,
 - 15 (10) -CO₂-C₁₋₄alkyl,
 - (11) -C(R³)(R⁴)-OH,
 - (12) -C(R³)(R⁴)-O-C₁₋₄alkyl, and
 - (13) -C₁₋₆alkyl-CO₂-R³;
- (d) mono-, di- or tri-substituted heteroaryl wherein the
20 heteroaryl is a monocyclic aromatic ring of 5 atoms, said
ring having one hetero atom which is S, O, or N, and
optionally 1, 2, or 3 additionally N atoms; or
the heteroaryl is a monocyclic ring of 6 atoms, said ring
25 having one hetero atom which is N, and optionally 1, 2, 3,
or 4 additional N atoms; said substituents are selected from
the group consisting of
 - (1) hydrogen,
 - (2) halo, including fluoro, chloro, bromo and iodo,
 - (3) C₁₋₆alkyl,
 - 30 (4) C₁₋₆alkoxy,
 - (5) C₁₋₆alkylthio,
 - (6) CN,
 - (7) CF₃,
 - (8) N₃,

- (9) -C(R³)(R⁴)-OH, and
(10) -C(R³)(R⁴)-O-C₁₋₄alkyl;
(e) benzoheteroaryl which includes the benzo fused analogs of (d);

5 R³, R⁴, R⁵ and R^{5'} are each independently selected from the group consisting of

- (a) hydrogen,
(b) C₁₋₆alkyl.

10 For purposes of this specification a compound shall be defined as a selective cyclooxygenase-2 inhibitor if the ratio of its IC₅₀ for the inhibition of cyclooxygenase-1 divided by its IC₅₀ for the inhibition of cyclooxygenase-2, as measured as described in this specification or a comparable method is 200 or greater; preferably 1000 or greater. Accordingly, other selective cyclooxygenase-2 inhibitors
15 within the scope of the invention include:



and other specific inhibitors disclosed in WO 94/13635, published June 23, 1994; US 5,344,911, issued September 6, 1994; and WO 94/15932,
25 published July 21 1994, all of which are hereby incorporated by reference.

In one genus the invention is directed to a method of preventing or treating osteoporosis, particularly in (but not limited to) post-menopausal women.


30 In a second genus the invention is directed to a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to substantially halt a loss of bone mass.

In a third genus the invention is directed to a method of reducing fractures in post-menopausal women or other patients who have suffered bone loss or have osteoporosis.

In a fourth genus the invention is directed to a method of maintaining bone density in post-menopausal women or other patients who susceptible to bone loss or have suffered bone loss or have osteoporosis.

5 Highly specific cyclooxygenase-2 inhibitors, such as compounds of formula I are also useful in the treatment of hypercalcemia of malignancy, osteolysis due to bone metastases, oral bone loss due to periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, and secondary forms
10 of osteoporosis such as immobilization-induced osteoporosis and osteoporosis resulting from glucocorticoid treatment, hyperthyroidism and thyroid hormone (T₃, T₄) treatment.

Each of these categories embraces the use of compounds of Formula Ia



Ia

25 or pharmaceutically acceptable salts thereof wherein:

R¹ is selected from the group consisting of

- 30
- (a) S(O)₂CH₃,
 - (b) S(O)₂NH₂,
 - (c) S(O)₂NHC(O)CF₃,
 - (d) S(O)NHCH₃,
 - (e) S(O)NHNH₂, and
 - (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁₋₆alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of

- 5 (1) hydrogen,
- (2) halo,
- (3) C₁₋₆alkoxy,
- (4) C₁₋₆alkylthio,
- (5) CN,
- 10 (6) CF₃,
- (7) C₁₋₆alkyl,
- (8) N₃,
- (9) -CO₂H,
- (10) -CO₂-C₁₋₄alkyl,
- 15 (11) -C(R³)(R⁴)-OH,
- (12) -C(R³)(R⁴)-O-C₁₋₄alkyl, and
- (13) -C₁₋₆alkyl-CO₂-R³;

(d) heteroaryl

(e) benzoheteroaryl

20 R³, R⁴, R⁵ and R^{5'} are each independently selected from the group consisting of

- (a) hydrogen,
- (b) C₁₋₆alkyl.

25 Within this class is the sub-class of compounds of Formula Ia wherein

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- 30 (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁₋₄alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono- or di-substituted phenyl wherein the substituent is
selected from the group consisting of
- 5 (1) hydrogen,
(2) fluoro, chloro, and bromo,
(3) C₁₋₄alkoxy,
(4) C₁₋₄alkylthio,
(5) CN,
10 (6) CF₃,
(7) C₁₋₄alkyl,
(8) N₃,
(9) -CO₂H,
(10) -CO₂-C₁₋₃alkyl,
15 (11) -C(R³)(R⁴)-OH, and
(12) -C(R³)(R⁴)-O-C₁₋₃alkyl,
- (d) mono- or di-substituted heteroaryl selected from the group
consisting of
- 20 (1) furanyl,
(2) diazinyl, triazinyl and tetrazinyl,
(3) imidazolyl,
(4) isooxazolyl,
(5) isothiazolyl,
(6) oxadiazolyl,
25 (7) oxazolyl,
(8) pyrazolyl,
(9) pyrrolyl,
(10) thiadiazolyl,
(11) thiazolyl,
30 (12) thienyl,
(13) triazolyl, and
(14) tetrazolyl,
- wherein said substituents are selected from the group consisting
of

- (a) hydrogen,
- (b) fluoro, chloro, bromo,
- (c) C₁₋₄alkoxy,
- (d) C₁₋₄alkylthio,
- 5 (e) CN,
- (5) CF₃,
- (6) C₁₋₄alkyl,
- (7) N₃,
- (8) -C(R³)(R⁴)-OH,
- 10 (9) -C(R³)(R⁴)-O-C₁₋₄alkyl.

Within this sub-class is the group of compounds of Formula Ia wherein

R² is selected from the group consisting of

- 15 (a) cyclohexyl, and
 - (b) mono- or di-substituted phenyl, and
- wherein the substituents are selected from the group consisting of

- 20 (1) hydrogen,
- (2) halo,
- (3) C₁₋₄alkoxy,
- (4) C₁₋₄alkylthio,
- (5) CN,
- (6) CF₃,
- 25 (7) C₁₋₄alkyl,
- (8) N₃, and
- (9) -C(R³)(R⁴)-OH;

R³ and R⁴, are each independently selected from the group consisting of

- 30 (a) hydrogen,
- (b) methyl or ethyl,

R⁵ and R^{5'} are each hydrogen.

Within this sub-class are the compounds of Formula Ia wherein:

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)NHCH₃, and
- (d) S(O)NHNH₂;

5

R² is selected from the group consisting of

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

- (1) hydrogen,
- (2) halo, selected from the group consisting of fluoro, chloro and bromo,
- (3) C₁-3alkoxy,
- (4) C₁-3alkylthio,
- (5) CN, and
- (6) C₁-3alkyl;

10

15

Within this group are the compounds of Formula Ia wherein

R² is

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

- (1) hydrogen,
- (2) halo, selected from the group consisting of fluoro, chloro and bromo,
- (3) methoxy, and
- (4) methyl.

20

25

These compounds may be more particularly defined as the compounds of Formula Ia wherein

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃, and
- (b) S(O)₂NH₂,

30

R² is

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

- (1) hydrogen,
- (2) halo, selected from the group consisting of fluoro, chloro and bromo.

5 For purposes of this specification mono- or di-substituted heteroaryl of definition R² is defined as a mono- or di-substituted heteroaryl selected from the group consisting of

- (1) 2-furanyl,
- (2) 3-furanyl,
- 10 (3) 2-thienyl,
- (4) 3-thienyl,
- (5) 3-isoxazolyl,
- (6) 4-isoxazolyl,
- (7) 5-isoxazolyl,
- 15 (8) 3-isothiazolyl,
- (9) 4-isothiazolyl,
- (10) 5-isothiazolyl,
- (11) 2-oxazolyl,
- (12) 4-oxazolyl,
- 20 (13) 5-oxazolyl,
- (14) 2-thiazolyl,
- (15) 4-thiazolyl,
- (16) 5-thiazolyl,
- (17) 1,2,3-thiadiazol-4-yl,
- 25 (18) 1,2,3-thiadiazol-5-yl,
- (19) 1,2,4-thiadiazol-3-yl,
- (20) 1,2,4-thiadiazol-5-yl,
- (21) 1,3,4-thiadiazol-2-yl,
- (22) 1,2,5-thiadiazol-3-yl,
- 30 (23) 1,2,3-oxadiazol-4-yl,
- (24) 1,2,3-oxadiazol-5-yl,
- (25) 1,2,4-oxadiazol-3-yl,
- (26) 1,2,4-oxadiazol-5-yl,
- (27) 1,3,4-oxadiazol-2-yl,

- 5 (28) 1,2,5-oxadiazol-3-yl,
 (29) pyrazol-4-yl,
 (30) pyrazol-4-yl,
 (31) pyrazol-5-yl,
 (32) 1,2,3-triadiazol-4-yl,
 (33) 1,2,3-triadiazol-5-yl,
 (34) 1,2,4-triadiazol-3-yl,
 (35) 1,2,4-triadiazol-5-yl,
 10 (36) 1,2-diazinyl,
 (37) 1,3-diazinyl,
 (38) 1,4-diazinyl,
 (39) 1,2,3,4-tetrazin-5-yl,
 (40) 1,2,4,5-tetrazin-4-yl,
 (41) 1,3,4,5-tetrazin-2-yl, and
 15 (42) 1,2,3,5-tetrazin-4-yl,
 wherein the substituents are defined in any definition of R².

- 20 Within the mono- or di-substituted heteroaryl of R² is the
 group wherein the substituents are selected from the group consisting of
 (a) hydrogen,
 (b) fluoro or chloro,
 (c) C₁-3alkoxy,
 (d) C₁-6alkylthio,
 (e) CN,
 25 (5) CF₃,
 (6) C₁-3alkyl,
 (7) -C(R³)(R⁴)-OH;
 (8) -C(R³)(R⁴)-O-C₁-4alkyl.

30 Within the mono- or di-substituted heteroaryl of R₂
 immediately above, is the group wherein the heterocycles are selected
 from

- (1) 3-isoxazolyl,
 (2) 4-isoxazolyl,

- | | | |
|----|------|------------------------|
| | (3) | 5-isoxazolyl, |
| | (4) | 3-isothiazolyl, |
| | (5) | 4-isothiazolyl, |
| | (6) | 5-isothiazolyl, |
| 5 | (7) | 2-oxazolyl, |
| | (8) | 4-oxazolyl, |
| | (9) | 5-oxazolyl, |
| | (10) | 2-thiazolyl, |
| | (11) | 4-thiazolyl, |
| 10 | (12) | 5-thiazolyl, |
| | (13) | 1,2,3-thiadiazol-4-yl, |
| | (14) | 1,2,3-thiadiazol-5-yl, |
| | (15) | 1,2,4-thiadiazol-3-yl, |
| | (16) | 1,2,4-thiadiazol-5-yl, |
| 15 | (17) | 1,3,4-thiadiazol-2-yl, |
| | (18) | 1,2,5-thiadiazol-3-yl, |
| | (19) | 1,2,3-oxadiazol-4-yl, |
| | (20) | 1,2,3-oxadiazol-5-yl, |
| | (21) | 1,2,4-oxadiazol-3-yl, |
| 20 | (22) | 1,2,4-oxadiazol-5-yl, |
| | (23) | 1,3,4-oxadiazol-2-yl, |
| | (24) | 1,2,5-oxadiazol-3-yl, |
| | (25) | 1,2-diazinyl, |
| | (26) | 1,3-diazinyl, and |
| 25 | (27) | 1,4-diazinyl. |

Within the mono- or di-substituted heteroaryl of R²
 immediately above, is the group wherein the heterocycles are selected
 from

- | | | |
|----|-----|-----------------|
| 30 | (1) | 3-isothiazolyl, |
| | (2) | 4-isothiazolyl, |
| | (3) | 5-isothiazolyl, |
| | (4) | 2-oxazolyl, |
| | (5) | 4-oxazolyl, |

- 5 (6) 5-oxazolyl,
 (7) 2-thiazolyl,
 (8) 4-thiazolyl,
 (9) 5-thiazolyl,
 (10) 1,2-diazinyl,
 (11) 1,3-diazinyl, and
 (12) 1,4-diazinyl, and
 wherein the substituents are selected from the group consisting of
 10 (1) hydrogen,
 (2) fluoro or chloro,
 (3) C₁-3alkoxy,
 (4) C₁-3alkylthio,
 (5) CN,
 (6) C₁-3alkyl, and
 15 (7) -C(R³)(R⁴)-OH,
 wherein R³ and R⁴ are each independently hydrogen,
 methyl or ethyl.

For purposes of this specification alkyl is defined to include
 linear, branched, and cyclic structures, with C₁-6alkyl including
 20 including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl,
 hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and
 cyclohexyl. Similarly, C₁-6alkoxy is intended to include alkoxy groups
 of from 1 to 6 carbon atoms of a straight, branched, or cyclic
 configuration. Examples of lower alkoxy groups include methoxy,
 25 ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the
 like. Likewise, C₁-6alkylthio is intended to include alkylthio groups of
 from 1 to 6 carbon atoms of a straight, branched or cyclic
 configuration. Examples of lower alkylthio groups include methylthio,
 propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration,
 30 the propylthio group signifies -SCH₂CH₂CH₃.

Exemplifying the invention are:

- (a) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-
 (5H)-furanone,

- (b) 3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone,
- (c) 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 5 (d) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (e) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 10 (f) 5,5-Dimethyl-3-(3-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (g) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (h) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 15 (i) 5,5-Dimethyl-3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (j) 5,5-Dimethyl-3-(3,4-dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 20 (k) 5,5-Dimethyl-3-(4-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (l) 3-(2-Naphyhyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- (m) 5,5-Dimethyl-3-(2-naphyhyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
- 25 (m) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone.

Further illustrating the invention are

- 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, and
- 30 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, or a pharmaceutically acceptable salt thereof.

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved,
5 enantiomerically pure forms and pharmaceutically acceptable salts thereof.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

10 In a second embodiment, the invention encompasses pharmaceutical compositions for treatment of osteoporosis.

Within this embodiment the invention encompasses pharmaceutical compositions for treatment of osteoporosis comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically
15 effective amount of compound of Formula I as described above.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic
20 ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium,
25 zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion
30 exchange resins, such as arginine, betaine, caffeine, choline, N,N_-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine,

piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

5 It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

As indicated above, pharmaceutical compositions for treating osteoporosis as defined may optionally include one or more ingredients as listed above.

10 The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active

ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening,
5 flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying
10 agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain
15 sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may
20 be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-
25 acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be
30 employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-

irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

5 For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)

10 Dosage levels of the order of from about 0.01 mg to about 100 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 6 g per patient per day. For example, osteoporosis may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day. A dosage 1.0 to 100 mg/kg per day or 1.0 to 20 mg/kg per day may prove especially useful.

20 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between 25 from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

30 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

Methods of Synthesis

The compounds of the present invention can be prepared according to the following methods.

5 Method A:

 An appropriately substituted aryl bromomethyl ketone II is reacted with an appropriately substituted aryl acetic acid III in a solvent such as acetonitrile in the presence of a base such as triethylamine and then treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to afford
10 the lactone IV. Isomeric lactone VII is prepared by reacting phenylacetic acid V with bromoketone VI under similar conditions.


15

20

25

30


METHOD A



Method B:

Methyl 2-hydroxy isobutyrate VIII is silylated with TMSCl to give the TMS ether IX, which is treated with the organometallic X to provide ketone XI. Desilylation followed by acylation yields keto-ester XIV, which can be cyclized to lactone XV by base catalysis. Oxidation of XV with MMPP or mCPBA affords the desired product XVI.

METHOD B



5




15

25

30

METHOD D




20 By reacting an acetylene XVIII with carbon monoxide and water in the presence of suitable catalysts, a mixture of compound IV and its isomer VII is obtained. The isomers are separable by standard procedures in the art such as chromatography or crystallization.

25 Examples of useful catalysts and conditions are PdCl₂ in aqueous HCl and EtOH, heated at 50-150°C and 50-150 atmospheres of pressure, or Rh₄(CO)₁₂ (or Rh₆(CO)₁₆) in aqueous THF (or acetone, acetonitrile, benzene, toluene, EtOH, MeOH) containing a trialkylamine, at 50-150°C and 20-300 atmospheres pressure. See Takahashi *et al.*,

30 *Organometallics* 1991, 10, 2493-2498; and Tsuji *et al.*, *J. Am. Chem. Soc.* 1966, 88, 1289-1292.

METHOD E



30

1, 4-Addition to XIX of 4-methylthiophenyl organometallic reagents X in the presence of copper salts and the trapping of the resultant enolate with trialkyl silyl chloride such as TMSCl or TIPSCl provide the ketene acetal XX. The ketene acetal can then be oxidized to the substituted butenolide XXI by the method of Ito using Pd(OAc)_2 or catalytic amounts of Pd(OAc)_2 and Cu(OAc)_2 with O_2 in MeOH or by the method of Magnus using PhIO/TMSN_3 and Bu_4NF . Introduction of

the iodine can be accomplished by treating XXI with I₂ in the presence of pyridine to afford XXII. Palladium catalyzed Suzuki or Stille coupling of XXIII with the appropriate aryl or alkyl partner such as the boronic acid XXIII provides the butenolide XXIV. The sulfide can be oxidized to a sulfone by various oxidizing agents such as peracetic acid, MPPM, MMPP or H₂O₂ to give the desired compound XXV. See Y. Ito *et al.*, *J. Am. Chem. Soc.* **1979**, *101*, 494, footnote 2; and P. Magnus *et al.*, *Tet. Lett.* **1992**, 2933.

10 Representative Compounds

Tables I and II illustrate compounds of Formula I.

15

20

25

30

TABLE I




		Example	Method
5		1	A
10			
15			
20		2	A
25			
30		3	B

TABLE I (continued)





		Example	Method
5		4	A
10		5	A
15			
20		6	A
25		7	A
30			

TABLE I (continued)



		Example	Method
5		8	A
10			
15		9	A
20		10	A
25		11	A
30			

TABLE I (continued)





		Example	Method
5		12	A
10			
15		13	A
20		14	A
25		15	A
30			

TABLE I (continued)





		Example	Method
5		16	A
10			
15		17	A
20			
25		18	A
30		19	A

TABLE I (continued)





		Example	Method
5		20	A
10		21	A
15			
20		22	A
25		23	A
30			

TABLE I (continued)


Table I (continued)

5

Example

Method


10



24

A


15



25

A


20



26

A

30



27

A

TABLE I (continued)





		Example	Method
5			
		28	A
10			
		29	A
15			
		30	A
20			
		31	A
25			
30			

TABLE I (continued)





		Example	Method
5		32	A
10			
15		33	A
20			
25		34	A
30			
		35	A

TABLE I (continued)





5		36	A
10		37	A
15			
20		38	A
25			
30		39	A

TABLE I (continued)



		Example	Method
5		40	A
10			
15		41	A
20		42	A
25		43	A
30			

TABLE I (continued)




		Example	Method
5		44	B + C
10			
15		45	B + C
20			
25		46	B + C
30			

TABLE I (continued)





	Example	Method	
5			
		47	B + C
10			
		48	B + C
15			
20			
25			
30			

TABLE II


5




10



15





20





25

30


5



10



15





20

25



30

TABLE II (continued)

5





10



15

20





25



30

TABLE II (continued)

5





10



15


20



25

30

TABLE II (concluded)



The compounds of the invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

30

(i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer

chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with
 5 different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta (δ)
 10 values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic
 15 signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

20 The following abbreviations have the indicated meanings:

	Ac	=	acetyl
	Bn	=	benzyl
	DBU	=	1,8-diazabicyclo[5.4.0]undec-7-ene
25	DIBAL	=	diisobutylaluminum hydride
	DMAP	=	4-(dimethylamino)pyridine
	DMF	=	N,N-dimethylformamide
	Et ₃ N	=	triethylamine
	LDA	=	lithium diisopropylamide
30	m-CPBA	=	metachloroperbenzoic acid
	MMPP	=	monoperoxyphthalic acid
	MPPM	=	monoperoxyphthalic acid, magnesium salt 6H ₂ O
	Ms	=	methanesulfonyl = mesyl = SO ₂ Me
	MsO	=	methanesulfonate = mesylate

	NSAID	=	non-steroidal anti-inflammatory drug
	OXONE®	=	2KHSO ₅ •KHSO ₄ •K ₂ SO ₄
	PCC	=	pyridinium chlorochromate
	PDC	=	pyridinium dichromate
5	Ph	=	phenyl
	Phe	=	benzenediyl
	Pye	=	pyridinediyl
	r.t	=	room temperature
	rac.	=	racemic
10	SAM	=	aminosulfonyl or sulfonamide or SO ₂ NH ₂
	TBAF	=	tetra-n-butylammonium fluoride
	Th	=	2- or 3-thienyl
	TFAA	=	trifluoroacetic acid anhydride
	THF	=	tetrahydrofuran
15	Thi	=	thiophenediyl
	TLC	=	thin layer chromatography
	TMS-CN	=	trimethylsilyl cyanide
	Tz	=	1H (or 2H)-tetrazol-5-yl
20	C ₃ H ₅	=	allyl

Alkyl Group Abbreviations

	Me	=	methyl
	Et	=	ethyl
	n-Pr	=	normal propyl
25	i-Pr	=	isopropyl
	n-Bu	=	normal butyl
	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl
30	c-Pr	=	cyclopropyl
	c-Bu	=	cyclobutyl
	c-Pen	=	cyclopentyl
	c-Hex	=	cyclohexyl

EXAMPLE 1**3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone****5 Step 1: 2-Bromo-1-(4-(methylsulfonyl)phenyl)ethanone**

A solution of 197 g of 4-(methylthio)acetophenone (ref: *JACS*, 1952, 74, p. 5475) in 700 mL of MeOH and 3500 mL of CH₂Cl₂ was added 881 g of MMPP over a period of 30 min. After 3 h at room temperature the reaction mixture was filtered and the filtrate
10 was washed with 2 L of saturated aqueous solution of NaHCO₃ and 1 L of brine. The aqueous phase was further extracted with 2 L of CH₂Cl₂. The combined extracts was dried over Na₂SO₄ concentrated to give 240 g of 4-(methylsulfonyl)acetophenone as a white solid.

To a cooled (-5 °C) solution of 174 g of 4-(methylsulfonyl)acetophenone in 2.5 L of CHCl₃ was added 20 mg of AlCl₃,
15 followed by a solution of 40 mL of Br₂ in 300 mL CHCl₃. The reaction mixture was then treated with 1.5 L of water and the CHCl₃ was separated. The aqueous layer was extracted with 1 L of EtOAc. The combined extracts was dried over Na₂SO₄ and concentrated. The
20 crude product was recrystallized from 50/50 EtOAc/hexane to give 210 g of the title compound as a white solid.

Step 2:

To the product of Step 1 (216 mg) dissolved in acetonitrile
25 (4 mL) was added Et₃N (0.26 mL), followed by 4-fluorophenylacetic acid (102 mg). After 1.5 h at room temperature 0.23 mL of DBU was added. The reaction mixture was stirred for another 45 min and then treated with 5 mL of 1 N HCl. The product was extracted with EtOAc, dried over Na₂SO₄ and concentrated. The residue was purified by flash
30 chromatography (40% EtOAc in hexane) to yield 150 mg of the title compound as a solid.

¹H NMR (CD₃COCD₃) δ 3.15 (3H, s), 5.36 (3H, s), 7.18 (2H, J=8.9 Hz, t), 7.46 (2H, m), 7.7 (2H, J=8.65 Hz, d), 7.97 (2H, J=8.68, d).

EXAMPLE 2

3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2*H*)-furanone

- 5 ¹H NMR (CD₃COCD₃) δ 5.34 (2H, s), 6.67 (2H, bd), 7.18 (2H, m),
7.46 (2H, m), 7.61 (2H, m), 7.90 (2H, m).
M.P. 187-188°C (d).

EXAMPLE 3

10

5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

- 15 Step 1: Methyl 2-trimethylsilyloxyisobutyrate
To a solution of 1.2 mL (10.4 mmol) of methyl 2-hydroxy-isobutyrate in 50 mL of CH₂Cl₂ were added 1.2 g (17.6 mmol) of imidazole and 2.1 mL (16.6 mmol) of TMSCl. The mixture was stirred at r.t. for 1.5 h and quenched with 20 mL of H₂O. The organic layer was dried over MgSO₄, concentrated and passed through a short plug of
20 silica gel eluted with 9:1 hexane/EtOAc. Evaporation of solvent afforded 1.27 g of the title compound as a colorless oil.
¹H NMR (CD₃COCD₃) δ 0.08 (9H, s), 1.38 (6H, s), 3.67 (3H, s).

- 25 Step 2: 2-Trimethylsilyloxy-4'-(methylthio)isobutyrophenone
A solution of 204 mg (1.0 mmol) of 4-bromothioanisole in 2.5 mL of THF was cooled to -78°C and treated with 0.42 mL of 2.5 M n-BuLi solution in hexane. After stirring at -78°C for 1 h, a solution of 380 mg (2.0 mmol) of methyl 2-trimethylsilyloxyisobutyrate in 2 mL of THF was added. The mixture was stirred at -78°C for 2 h and then
30 quenched with NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The residue was purified by flash chromatography, eluting with 19:1 hexane/EtOAc to give 95 mg of the title product.

¹H NMR (CD₃COCD₃) δ 0.05 (9H, s), 1.52 (6H, s), 2.53 (3H, s), 7.33 (2H, d), 8.12 (2H, d).

Step 3: 2-Hydroxy-4'-(methylthio)isobutyrophenone

5 To a solution of 40 mg (0.14 mmol) of 2-trimethylsilyloxy-4'-(methylthio)isobutyrophenone in 2 mL THF was added 0.2 mL of 1 M n-Bu₄NF in THF. The resulting mixture was stirred for 30 min and then quenched with 10 mL of NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The
10 residue was purified by flash chromatography, eluting with 4:1 hexane/EtOAc to give 25 mg of the title product.
¹H NMR (CD₃COCD₃) δ 1.50 (6H, s), 2.54 (3H, s), 4.68 (1H, s), 7.30 (2H, d), 8.15 (2H, d).

15 **Step 4: 2-(4-Fluorophenylacetoxy)-4'-(methylthio)isobutyrophenone**

To a solution of 72 mg (0.34 mmol) 2-hydroxy-4'-(methylthio)isobutyrophenone in 1.7 mL of CH₂Cl₂ were added 0.2 mL of pyridine and 140 mg (0.81 mmol) of 4-fluorophenylacetyl chloride.
20 The mixture was stirred at r.t. overnight and then quenched with NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography eluting with 8:1 hexane/EtOAc to give 95 mg of the title product.
25 ¹H NMR (CD₃COCD₃) δ 1.62 (3H, s), 1.67 (3H, s), 2.48 (3H, s), 3.79 (2H, s), 7.0-7.3 (6H, m), 7.78 (2H, d).

Step 5: 5,5-Dimethyl-3-(4-fluorophenyl-4-(4-(methylthio)phenyl)-2-(5H)-furanone

30 To a solution of 95 mg of 2-(4-fluorophenylacetoxy)-4'-(methylthio)isobutyrophenone in 4 mL of CH₂Cl₂ was added 0.2 mL of DBU. The mixture was stirred for 4 h and diluted with NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and

concentrated. The residue was purified by flash chromatography, eluting with 20:1 toluene/EtOAc to give 75 mg of the title product. ¹H NMR (CD₃COCD₃) δ 1.58 (6H, s), 2.50 (3H, s), 7.03 (2H, dd), 7.25-7.35 (4H, m), 7.41 (2H, dd).

5

Step 6: 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)-phenyl)-2-(5H)-furanone

To a solution of 81 mg of 5,5-dimethyl-3-(4-fluorophenyl)-4-(4-(methylthio)phenyl)-2-(5H)-furanone in 1.8 mL of CH₂Cl₂ and 0.2 mL of MeOH was added 250 mg of MPPM. The reaction mixture was stirred at room temperature for 1 h and then quenched with aqueous NaHCO₃. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography eluting with 1:1 hexane/EtOAc to give 73 mg of the title product.

10

15

¹H NMR (CD₃COCD₃) δ 1.62 (6H, s), 3.15 (3H, s), 7.02 (2H, dd), 7.40 (2H, dd), 7.65 (2H, d), 8.03 (2H, d).

EXAMPLE 4

20

3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂F₂O₄S

C, 58.28; H, 3.45; S, 9.15

25

Found: C, 58.27; H, 3.50; S, 9.27

EXAMPLE 5

3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30

To a solution of 3,4-difluorophenylacetic acid (ALDRICH CHEMICAL) (10 g) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Example 9, Step 1) (17.3 g) in acetonitrile (200 mL) at room temperature was added slowly Et₃N (20.2 mL). After 1 h at r.t., the mixture was cooled in an ice bath and

treated with 17.4 mL of DBU. After 2 h at 0°C, the mixture was treated with 200 mL of 1 N HCl and the product was extracted with EtOAc, dried over Na₂SO₄ and concentrated. The residue was applied on top of a silica gel plug (sintered glass funnel) eluted with 75%
 5 EtOAc/hexane, giving, after evaporation of the solvent and swishing in EtOAc, 10 g of the title compound.

Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
 10 Found: C, 58.02; H, 3.51; S, 9.35

EXAMPLE 6

15 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
 Found: C, 58.18; H, 3.50; S, 9.44

20 EXAMPLE 7

3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

25 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
 Found: C, 58.89; H, 3.51; S, 9.11

30

EXAMPLE 8

3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₂F₂O₄S
 C, 58.28; H, 3.45; S, 9.15
Found: C, 58.27; H, 3.62; S, 9.32

EXAMPLE 9

10

3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₃BrO₄S
 C, 51.94; H, 3.33; S, 8.16
15 Found: C, 51.76; H, 3.42; S, 8.21

EXAMPLE 10

20

3-(4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

¹H NMR (300 MHz, CDCl₃) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (4H, m),
5.16 (2H, s), 3.06 (3H, s)

EXAMPLE 11

25

3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₈H₁₆O₅S
 C, 62.78 H, 4.68; S, 9.31
30 Found: C, 62.75; H, 4.72; S, 9.39

EXAMPLE 12**3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone**

To a solution of phenylacetic acid (27.4 g, 201 mmol) and
5 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Example 1, Step 1) (60
g, 216 mmol, 1.075 eq.) in acetonitrile (630 mL) at 25°C was added
slowly Et₃N (30.8 mL, 1.1 eq.). The mixture was stirred for 20 min.
at room temperature and then cooled in an ice bath. DBU (60.1 mL, 3
eq.) was slowly added. After stirring for 20 min. in the ice bath, the
10 reaction was complete and the mixture was acidified with 1 N HCl
(color changes from dark brown to yellow). Then 2.4 L of ice and
H₂O were added, stirred for a few minutes, then the precipitate was
filtered and rinsed with H₂O (giving 64 g of crude wet product). The
solid was dissolved in 750 mL of CH₂Cl₂ (dried over MgSO₄, filtered)
15 and 300 g of silica gel was added. The solvent was evaporated to near
dryness (silica gel a bit sticky) and the residue was applied on top of a
silica gel plug (sintered glass funnel), eluted with 10% EtOAc/CH₂Cl₂,
giving, after evaporation of the solvent and swishing in EtOAc, 36.6 g
(58%) of the title compound.

20

Analysis calculated for C₁₇H₁₄O₄S
 C, 64.95; H, 4.49; S, 10.20
Found: C, 64.63; H, 4.65; S, 10.44

25

EXAMPLE 12A**3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone**

Into a 20 mL glass ampule are added 1 g of 2-(4-(methyl-
sulfonyl)phenyl)phenylacetylene, 20 mg of Rh₄(CO)₁₂, 1.5 g of Et₃N,
30 10 mL of THF, 1 mL of H₂O under a nitrogen atmosphere, and the
ampule is placed in a 100-mL stainless steel autoclave. The reaction
system is flushed three times with CO then charged at r.t. to an initial
CO pressure of 100 atm. The reaction is carried at 100 °C for 5 h. The
solution is then diluted with 50 mL of benzene and washed with brine

and 1 N HCl. The benzene solution is dried over Na₂SO₄, and concentrated. The crude products are separated by column chromatography on silica gel, eluting with 2:1 EtOAc/hexane to give the title compound and its regioisomer, 4-(phenyl)-3-(4-(methylsulfonyl)-phenyl)-2-(5H)-furanone.

EXAMPLE 12B

10 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Step 1: 2-trimethylsilyloxy-4-(4-(methylthio)phenyl)-3,4-dihydrofuran

To a solution of 3.86 g (19 mmol) of 4-bromothioanisole in 90 mL of Et₂O cooled at -78°C, is added 22 mL of 1.7 M solution of t-BuLi in pentane (38 mmol) dropwise. The reaction mixture is stirred for 15 min at -78°C and 3.8 g of CuI is added and the reaction mixture is allowed to warm to -40 °C over a period of 30 min. A solution of 1.7 g of 2(5H)-furanone in 10 mL of THF is added. After stirring for 1 h, 2 mL of freshly distilled TMSCl is added dropwise. The reaction mixture is then treated with 2 mL of Et₃N and 50 mL of sat. NaHCO₃, and extracted with 100 mL of Et₂O. The Et₂O layer is dried over Na₂SO₄ and concentrated to give the crude title compound which is used for the next step without further purification.

25 Step 2: 4-(4-(methylthio)phenyl)-2-(5H)-furanone

To a solution of 4 g of Pd(OAc)₂ in 100 mL of acetonitrile is added dropwise the crude product from Step 1(5 g) under nitrogen at r.t. After 10 h at r.t., the mixture is condensed under reduced pressure and the residue is purified by flash chromatography on silica gel eluted with 2:1 hexane/EtOAc to give the title compound.

Step 3: 3-iodo-4-(4-(methylthio)phenyl)-2-(5H)-furanone

To a solution of 3 g of the product of Step 2 in 30 ml of pyridine is added 8.7 g of I₂. The mixture is stirred for 24 h and then

diluted with 200 mL of Et₂O, washed with 100 mL of 5 N HCl and 50 mL of 5 N Na₂S₂O₃. The Et₂O layer is dried over Na₂SO₄ and concentrated to give the title compound.

5 **Step 4:** 3-(Phenyl)-4-(4-(methylthio)phenyl)-2-(5H)-furanone

A mixture of 4 g of the product of Step 3, 3.7 g of PhB(OH)₂, 0.4 g of Ph₃As, 0.4 g of PdCl₂(PhCN)₂ in 100 mL of benzene and 15 mL of 2 N NaOH is refluxed for 6 h. Ether (200 mL) is then added and the mixture is washed with 100 mL of saturated
10 NaHCO₃. The organic layer is dried over MgSO₄ and concentrated. The residue is purified by flash chromatography on silica gel eluted with 4:1 hexane/EtOAc to give the title compound.

15 **Step 5:** 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

To a solution of 3 g of the product of Step 4 in 80 mL of 10:1 CH₂Cl₂/MeOH is added 5.5 g of MPPM. The reaction mixture is stirred at room temperature for 2 h and then diluted with 100 mL of 1:1 hexane/EtOAc. After filtration and concentration, the residue is
20 purified by flash chromatography eluted with 2:1 EtOAc/hexane to give the title product.

EXAMPLE 13

25 3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for C₁₇H₁₃ClO₄S

C, 58.54; H, 3.76; S, 9.19

Found: C, 58.59; H, 3.80; S, 9.37

EXAMPLE 14

3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

5

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.75; H, 2.93
Found: C, 49.75; H, 3.01

10

EXAMPLE 15

3-(2-Bromo-4-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

15 ¹H NMR (300 MHz, acetone-d₆) δ 7.95 (2H, d), 7.85 (1H, d), 7.63 (2H, dd), 7.55 (1H, dd), 7.45 (1H, d), 5.50 (2H, s), 3.15 (3H, s)

EXAMPLE 16

20 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.50-7.30 (3H, m), 5.35 (2H, s), 3.15 (3H, s)

25

EXAMPLE 17

3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

30

Analysis calculated for C₁₇H₁₂BrFO₄S
 C, 49.75; H, 2.93
Found: C, 49.44; H, 2.98

EXAMPLE 18

3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₃ClO₄S
 C, 58.54; H, 3.76
 Found: C, 58.29; H, 3.76

EXAMPLE 19

10

3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₂ClFO₄S
15 C, 55.67; H, 3.30
 Found: C, 55.67; H, 3.26

EXAMPLE 20

20

3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
 Found: C, 52.89; H, 3.23; S, 8.58
25

EXAMPLE 21

3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
 Found: C, 53.07; H, 3.32; S, 8.51

EXAMPLE 22

3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₁₇H₁₂Cl₂O₄S
 C, 53.28; H, 3.16; S, 8.37
 Found: C, 52.99; H, 3.22; S, 8.54

EXAMPLE 23

10

3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

15 ¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.60 (1H, d), 7.25-7.40 (2H, m), 5.35 (2H, s), 3.15 (3H, s)

EXAMPLE 24

20 **3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone**

¹H NMR (CD₃COCD₃) δ 8.10 (2H, d), 7.82-7.93 (4H, m), 7.75 (2H, d), 5.55 (2H, s), 3.30 (3H, s)

25

EXAMPLE 25

3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

30 Analysis calculated for C₁₈H₁₅FO₅S
 C, 59.66; H, 4.17
 Found: C, 59.92; H, 4.37

EXAMPLE 26

3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

5 Analysis calculated for C₁₈H₁₅ClO₅S
 C, 57.07; H, 3.99
Found: C, 57.29; H, 4.15

EXAMPLE 27

10

3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone

15 Analysis calculated for C₁₈H₁₅BrO₅S
 C, 51.08; H, 3.57
Found: C, 51.38; H, 3.62

EXAMPLE 28

20

3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

Analysis calculated for C₁₇H₁₃FO₄S
 C, 61.44; H, 3.94
Found: C, 61.13; H, 3.85

25

EXAMPLE 29

3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone

30 ¹H NMR (300 MHz, acetone-d₆) δ 8.0 (2H, d), 7.70 (2H, d), 7.35 (2H,
d), 7.25 (2H, d), 5.35 (2H, s), 3.15 (3H, s), 2.55 (3H, s)

EXAMPLE 30

3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 ^1H NMR (300 MHz, CDCl_3) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (1H, m),
7.12 (3H, m), 5.18 (2H, s), 3.06 (3H, s)

EXAMPLE 31

10 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

15 ^1H NMR (300 MHz, acetone- d_6) δ 8.0 (2H, d), 7.70 (2H, d), 7.55-7.65
(1H, m), 7.40 (1H, d), 7.30 (1H, m), 5.60 (2H, s), 3.15 (3H, s)

EXAMPLE 32

20 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

Analysis calculated for $\text{C}_{18}\text{H}_{15}\text{BrO}_4\text{S}$
 C, 53.08; H, 3.71
Found: C, 53.06; H, 3.83

25 EXAMPLE 33

3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone

30 Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{BrFO}_4\text{S}$
 C, 49.65; H, 2.94
Found: C, 49.76; H, 3.00

EXAMPLE 34

3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

- 5 ^1H NMR (300 MHz, acetone- d_6) δ 8.0 (2H, d), 7.80 (1H, d), 7.75 (3H, m), 7.25 (1H, d), 5.35 (2H, s), 3.15 (sH, s)

EXAMPLE 35

- 10 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{ClFO}_4\text{S}$
 C, 55.67; H, 3.30

- 15 Found: C, 55.45; H, 3.30

EXAMPLE 36

- 20 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{BrFO}_4\text{S}$
 C, 49.66; H, 2.94; S, 7.80

- 25 Found: C, 49.79; H, 3.01; S, 7.51

EXAMPLE 37

- 30 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Analysis calculated for $\text{C}_{17}\text{H}_{12}\text{BrClO}_4\text{S}$
 C, 47.74; H, 2.83; S, 7.50

Found: C, 47.92; H, 2.84; S, 7.42

EXAMPLE 38

3-(2-Naphthyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

5 Analysis calculated for C₂₁H₁₆O₄S
 C, 69.22; H, 4.43
 Found: C, 69.22; H, 4.46

EXAMPLE 39

10

3-(7-Quinoliny)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

 Analysis calculated for C₂₀H₁₅NO₄S
 C, 65.74; H, 4.14; N, 3.83
 15 Found: C, 65.34; H, 4.40; N, 3.80
 M.S. (DCI, CH₄) calculated for M⁺, 365
 Found for M⁺⁺1, 366

EXAMPLE 40

20

3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone

¹H NMR (400 MHz, CD₃COCD₃) δ 7.92 (2H, dd), 7.64 (3H, dm), 7.60
 (1H, dd), 7.32 (1H, dd), 6.70 (1H, bs), 5.38 (2H, s)
 25

EXAMPLE 41

3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone

30 ¹H NMR (400 MHz, CD₃COCD₃) δ 7.92 (2H, dd), 7.64 (2H, dd), 7.30-
 7.45 (2H, m), 7.22 (1H, m), 6.68 (2H, bs), 5.37 (2H, s)

EXAMPLE 42

3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-
furanone

5

Analysis calculated for C₁₇H₁₄ClNO₅S

C, 53.76; H, 3.72, N, 3.69

Found: C, 53.32; H, 3.84, N, 3.59

M.S. (DCI, CH₄) calculated for M⁺, 379

10

Found for M⁺+1, 380

EXAMPLE 43

3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-
furanone

15

Analysis calculated for C₁₇H₁₄BrNO₅S

C, 48.13; H, 3.33, N, 3.30

Found: C, 48.26; H, 3.40, N, 3.28

20

M.S. (DCI, CH₄) calculated for M⁺, 423

Found for M⁺+1, 424

Assays for Determining Biological Activity

25

The compound of the instant invention can be evaluated for efficacy by use of one or more of the following assays. As appreciated by those of skill in the art, the efficacy of a compound within the scope of the invention may be determined by statistical comparison of results achieved in the presence of that compound to that which is achieved in its absence. Alternative may also be utilized

30

BONE RESORPTION (PIT) ASSAY

When osteoclasts engage in bone resorption, they will literally cause the formation of pits in the surface of bone that they are acting upon. Therefore, when testing compounds for their ability to

inhibit osteoclasts, it is useful to measure the ability of osteoclasts to excavate these resorption pits when the inhibiting compound is present.

Preparation of bone slices:

5 Bone slices (20 μ m) are obtained by cutting 5 mm sections of bovine bone cylinders taken from bovine femur diaphysis using a low-speed diamond saw (Isomet, Buehler, Ltd., Lake Bluff, IL) following by the method of Arnett and Dempster, Endocrinology 120:602-608, 1987.

10 Slices are cleaned by ultrasonication, 3X in distilled water at 15 mins each. The slices are then rinsed in distilled water and placed in a 96-well plates. The plates are then placed in a tissue culture hood under uv light to sterilize and dry the bone slices. Prior to incubation with osteoclasts, bone slices were rehydrated in 0.1 ml complete
15 medium 199 with 1% antimycotic/antibiotics (GIBCO, New York) and 10% fetal calf serum for 60 min.

Preparation of osteoclasts:

20 Rat long bones (tibiae, femora, humeri) are obtained from newborn rats (1-3 days old), cleaned of adherent tissue and minced in ice with scalpel blades in 3 ml Medium 199. The resulting suspension was gently pipetted 120 times with a wide-bore pipet and adjusted such that 750 μ l of media is utilized for a preparation from one rat. The cell suspension is then filtered through a 100 μ m nylon cell strainer
25 (Falcon). The resulting suspension is then aliquoted at 100 μ m/well. Finally, 22 μ l of a 10X concentration of test drug is added to each well.

Incubation, staining and quantitation of pits:

30 Osteoclasts and bone slices are incubated for 24 hrs, the bone slices are washed 2X in PBS, then fixed with 2.5% glutaraldehyde/0.1 M cacodylate (100 μ l/well) for at least 20 mins. The bone slices are then washed for 2X in PBS and sonicated for 2 min in 0.25 M NH₄OH at 100 μ l/well in order to strip the cells from the lacunae. The bones are subsequently sonicated twice more in distilled

water, 15 min each. The bone slices are stained in the wells with 1% toluidine blue/1% sodium borate for 5-7 min. The bone slices are dried and the number of pits are counted by epi-fluorescence.

5

10

15

20

25

30

OCFORM ASSAY

Osteoblast-like cells (1.8 cells), originally derived from mouse calvaria, are plated in CORNING 24 well tissue culture plates in α MEM medium containing ribo- and deoxyribonucleosides, 10% fetal bovine serum and penicillin-streptomycin. Cells are seeded at 40,000/well in the morning. In the afternoon, bone marrow cells are prepared from six week old male Balb/C mice as follows:

Mice are sacrificed, tibiae removed and placed in the above medium. The ends are cut off and the marrow is flushed out of the cavity into a tube with a 1 mL syringe with a 27.5 gauge needle. The marrow is suspended by pipetting up and down with a glass pasteur pipette. The suspension is passed through two layers of approximately 400 μ m mesh stainless steel cloth. The resulting suspension is centrifuged at 350 x g for seven minutes. The pellet is resuspended, and a sample is diluted in 2% HOAC to lyse the red cells. The remaining cells are counted in a hemocytometer. The cells are pelleted and resuspended at 1×10^6 cells/mL. 50 μ L is added to each well to yield 50,000 cells/well and 1,25-dihydroxy-vitamin D₃(D₃) is added to each well to a final concentration of 10 nM. The cultures are incubated at 37°C in a humidified, 5% CO₂ atmosphere. After 48 h, the medium is changed. 72 h after the addition of bone marrow, test compounds are added with fresh medium containing D₃ to triplicate wells. Compounds are added again after 48 h with fresh medium containing D₃. After an additional 24 h the medium is removed, cells are fixed with 10% formaldehyde in phosphate buffered saline for 10 minutes at r.t., followed by a 1-2 minute treatment with EtOH:acetone (1:1) and air dried. The cells are then stained for tartrate resistant acid phosphatase as follows:

The cells are stained for 10-15 minutes at room temperature with 50 mM acetate buffer, pH 5.0 containing 30 mM sodium tartrate, 0.3 mg/mL Fast Red Violet LB Salt and 0.1 mg/mL Naphthol AS -MX phosphate. After staining, the plates are washed

extensively with deionized water and air dried. The number of multinucleated, positively staining cells are counted in each well.


5 While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses as set forth herein above may be applicable as a consequence of
10 variations in the responsiveness of the mammal being treated for severity of bone disorders caused by resorption, or for other indications for the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether
15 there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims
20 which follow and that such claims be interpreted as broadly as is reasonable.

25

30

WHAT IS CLAIMED IS:

1. A method of inhibiting bone resorption in a patient
in need of such inhibition comprising:
5 administration of a non-toxic therapeutically effective amount of a
selective cyclooxygenase-2 inhibitor.
2. A method of preventing, retarding, halting or
reversing loss of bone mass in a patient in need of such prevention
10 comprising:
administration of a non-toxic therapeutically effective amount of a
selective cyclooxygenase-2 inhibitor.
3. A method of reducing fractures in a patient in need
15 of such reduction comprising:
administration of a non-toxic therapeutically effective amount of a
selective cyclooxygenase-2 inhibitor.
4. A method of preventing, retarding, halting or
20 reversing osteoporosis in a patient in need of such prevention
comprising:
administration of a non-toxic therapeutically effective amount of a
selective cyclooxygenase-2 inhibitor.
- 25 5. A method of maintaining bone density in a patient in
need of such maintenance comprising:
administration of a non-toxic therapeutically effective amount of a
selective cyclooxygenase-2 inhibitor.
- 30 6. A method according to Claim 1 wherein the inhibitor
is a compound of Formula Ia



Ia

or pharmaceutically acceptable salts thereof wherein:

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁-6alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of

selected from the group consisting of

- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃,
- (7) C₁-6alkyl,
- (8) N₃,
- (9) -CO₂H,

- (10) $-\text{CO}_2\text{-C}_{1-4}\text{alkyl}$,
- (11) $-\text{C}(\text{R}^3)(\text{R}^4)\text{-OH}$,
- (12) $-\text{C}(\text{R}^3)(\text{R}^4)\text{-O-C}_{1-4}\text{alkyl}$, and
- (13) $-\text{C}_{1-6}\text{alkyl-CO}_2\text{-R}^3$;

5

- (d) heteroaryl
- (e) benzoheteroaryl

R^3 , R^4 , R^5 and $\text{R}^{5'}$ are each independently selected from the group consisting of

10

- (a) hydrogen,
- (b) $\text{C}_{1-6}\text{alkyl}$.

7. A method according to Claim 6 wherein

R^1 is selected from the group consisting of

15

- (a) $\text{S}(\text{O})_2\text{CH}_3$, and
- (b) $\text{S}(\text{O})_2\text{NH}_2$.

R^2 is

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

20

- (1) hydrogen,
- (2) halo, selected from the group consisting of fluoro, chloro and bromo; and

R^5 and $\text{R}^{5'}$ are each hydrogen.


25

8. A method according to Claim 7 wherein the compound of Formula Ia is

30

3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone, 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone, or a pharmaceutically acceptable salt thereof.

9. A method according to Claim 2 wherein the inhibitor is a compound of Formula Ia



Ia

or pharmaceutically acceptable salts thereof wherein:

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁-6alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of


- selected from the group consisting of
- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃,
- (7) C₁-6alkyl,

- 5 (8) N₃,
(9) -CO₂H,
(10) -CO₂-C₁₋₄alkyl,
(11) -C(R³)(R⁴)-OH,
(12) -C(R³)(R⁴)-O-C₁₋₄alkyl, and
(13) -C₁₋₆alkyl-CO₂-R³;
(d) heteroaryl
(e) benzoheteroaryl
10 R³, R⁴, R⁵ and R^{5'} are each independently selected from
the group consisting of
(a) hydrogen,
(b) C₁₋₆alkyl.

- 15 10. A method according to Claim 9 wherein
R¹ is selected from the group consisting of
(a) S(O)₂CH₃, and
(b) S(O)₂NH₂,
R² is
20 mono or di-substituted phenyl wherein the substituents are
selected from the group consisting of
(1) hydrogen,
(2) halo, selected from the group consisting of fluoro,
chloro and bromo; and
25 R⁵ and R^{5'} are each hydrogen.

11. A method according to Claim 10 wherein the
compound of Formula Ia is
30 3-(3,4-Difluorophenyl)-4-(4-
(methylsulfonyl)phenyl)-2-(5*H*)-furanone,
3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone, or a pharmaceutically acceptable salt
thereof.

12. A method according to Claim 3 wherein the inhibitor is a compound of Formula Ia



Ia

or pharmaceutically acceptable salts thereof wherein:

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁-6alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of


- selected from the group consisting of
- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃,
- (7) C₁-6alkyl,

- 5 (8) N₃,
(9) -CO₂H,
(10) -CO₂-C₁₋₄alkyl,
(11) -C(R³)(R⁴)-OH,
(12) -C(R³)(R⁴)-O-C₁₋₄alkyl, and
(13) -C₁₋₆alkyl-CO₂-R³;
(d) heteroaryl
(e) benzoheteroaryl
10 R³, R⁴, R⁵ and R^{5'} are each independently selected from
the group consisting of
(a) hydrogen,
(b) C₁₋₆alkyl.

- 15 13. A method according to Claim 12 wherein
R¹ is selected from the group consisting of
(a) S(O)₂CH₃, and
(b) S(O)₂NH₂.
R² is
20 mono or di-substituted phenyl wherein the substituents are
selected from the group consisting of
(1) hydrogen,
(2) halo, selected from the group consisting of fluoro,
chloro and bromo; and
25 R⁵ and R^{5'} are each hydrogen.

14. A method according to Claim 13 wherein the
compound of Formula Ia is
30 3-(3,4-Difluorophenyl)-4-(4-
(methylsulfonyl)phenyl)-2-(5*H*)-furanone,
3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
furanone, or a pharmaceutically acceptable salt
thereof.

15. A method according to Claim 4 wherein the inhibitor is a compound of Formula Ia



Ia

or pharmaceutically acceptable salts thereof wherein:

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁-6alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of


- selected from the group consisting of
- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃,
- (7) C₁-6alkyl,

- 5
- (8) N₃,
 - (9) -CO₂H,
 - (10) -CO₂-C₁₋₄alkyl,
 - (11) -C(R³)(R⁴)-OH,
 - (12) -C(R³)(R⁴)-O-C₁₋₄alkyl, and
 - (13) -C₁₋₆alkyl-CO₂-R³;
- (d) heteroaryl
- (e) benzoheteroaryl
- 10 R³, R⁴, R⁵ and R^{5'} are each independently selected from the group consisting of
- (a) hydrogen,
 - (b) C₁₋₆alkyl.

- 15 16. A method according to Claim 15 wherein R¹ is selected from the group consisting of
- (a) S(O)₂CH₃, and
 - (b) S(O)₂NH₂,
- R² is
- 20 mono or di-substituted phenyl wherein the substituents are selected from the group consisting of
- (1) hydrogen,
 - (2) halo, selected from the group consisting of fluoro, chloro and bromo; and
- 25 R⁵ and R^{5'} are each hydrogen.

17. A method according to Claim 16 wherein the compound of Formula Ia is
- 30 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone, 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-furanone, or a pharmaceutically acceptable salt thereof.

18. A method according to Claim 5 wherein the inhibitor is a compound of Formula Ia



Ia

or pharmaceutically acceptable salts thereof wherein:

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃;

R² is selected from the group consisting of

- (a) C₁-6alkyl,
- (b) C₃, C₄, C₅, C₆, and C₇, cycloalkyl,
- (c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of

- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃,
- (7) C₁-6alkyl,

- 5 (8) N₃,
(9) -CO₂H,
(10) -CO₂-C₁₋₄alkyl,
(11) -C(R³)(R⁴)-OH,
(12) -C(R³)(R⁴)-O-C₁₋₄alkyl, and
(13) -C₁₋₆alkyl-CO₂-R³;
(d) heteroaryl
(e) benzoheteroaryl
10 R³, R⁴, R⁵ and R^{5'} are each independently selected from
the group consisting of
(a) hydrogen,
(b) C₁₋₆alkyl.

- 15 19. A method according to Claim 16 wherein
R¹ is selected from the group consisting of
(a) S(O)₂CH₃, and
(b) S(O)₂NH₂,
R² is
20 mono or di-substituted phenyl wherein the substituents are
selected from the group consisting of
(1) hydrogen,
(2) halo, selected from the group consisting of fluoro,
chloro and bromo; and
25 R⁵ and R^{5'} are each hydrogen.

20. A method according to Claim 19 wherein the
compound of Formula Ia is
30 3-(3,4-Difluorophenyl)-4-(4-
(methylsulfonyl)phenyl)-2-(5H)-furanone,
3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-
furanone, or a pharmaceutically acceptable salt
thereof.

81

Patents Act 1977
Examiner's report to the Comptroller under Section 17
(The Search report)

Application number
 GB 9520615.7

Relevant Technical Fields

- (i) UK Cl (Ed.N) A5B (BHA, BJA, BJB)
 (ii) Int Cl (Ed.6) A61K

Search Examiner
 DR J HOULIHAN

Date of completion of Search
 31 JANUARY 1996

Databases (see below)

(i) UK Patent Office collections of GB, EP, WO and US patent specifications.

(ii) ONLINE: CAS ONLINE, DIALOG/MEDICINE, WPI

Documents considered relevant following a search in respect of Claims :-
 1-20

Categories of documents

- | | |
|--|---|
| <p>X: Document indicating lack of novelty or of inventive step.</p> <p>Y: Document indicating lack of inventive step if combined with one or more other documents of the same category.</p> <p>A: Document indicating technological background and/or state of the art.</p> | <p>P: Document published on or after the declared priority date but before the filing date of the present application.</p> <p>E: Patent document published on or after, but with priority date earlier than, the filing date of the present application.</p> <p>&: Member of the same patent family; corresponding document.</p> |
|--|---|

Category	Identity of document and relevant passages		Relevant to claim(s)
P,X	GB 2283745 A	(MERCK) page 2 lines 28-33; page 7 lines 26-34; Claim 7	1-5
P,X	WO 95/21817 A1	(SEARLE & CO) page 2 lines 4-9; page 4 line 6 - page 5 line 2; page 137 lines 13-26; Claims 36-51	1-5
P,X	WO 94/26731 A1	(MERCK) page 2 lines 10-31; page 6 lines 23-28; Claims 17, 19 and 20	1-5
X	WO 94/15932 A1	(SEARLE) page 2 lines 24-29; page 7 line 11 - page 8 line 4; page 27 lines 13-24; page 72 lines 23-35; page 74 lines 12-32; Claims 16-34	1-5
X	WO 94/13635 A1	(MERCK) page 12 line 18 - page 14 line 13; page 16 lines 8-32; Claims; Claims 22, 25 and 29	1-5
X	European J. Clin. Pharmacol. Vol. 47(1) 1994. Lemmel E M Suppl. A52 See Abstract		1-5

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).